The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...
A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...
A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...
A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.
Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued ...
Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
Outside the game, commercials are a big part of Super Bowl Sunday. Companies pay large amounts of money for their ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback